Last reviewed · How we verify
Higher bioavailability BNX sublingual tablets
Higher bioavailability BNX sublingual tablets is a Opioid partial agonist Small molecule drug developed by Orexo AB. It is currently FDA-approved for Opioid use disorder (maintenance treatment), Moderate to severe pain. Also known as: OX219, Zubsolv, Buprenorphine/naloxone sublingual tablets.
BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment.
BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment. Used for Opioid use disorder (maintenance treatment), Moderate to severe pain.
At a glance
| Generic name | Higher bioavailability BNX sublingual tablets |
|---|---|
| Also known as | OX219, Zubsolv, Buprenorphine/naloxone sublingual tablets |
| Sponsor | Orexo AB |
| Drug class | Opioid partial agonist |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain management; Opioid use disorder |
| Phase | FDA-approved |
Mechanism of action
Buprenorphine is a partial agonist at the mu-opioid receptor that provides analgesia and reduces cravings in opioid use disorder. The sublingual tablet formulation with improved bioavailability allows for more efficient absorption through the oral mucosa, bypassing first-pass hepatic metabolism and achieving higher systemic exposure compared to standard formulations.
Approved indications
- Opioid use disorder (maintenance treatment)
- Moderate to severe pain
Common side effects
- Headache
- Nausea
- Constipation
- Dizziness
- Sweating
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher bioavailability BNX sublingual tablets CI brief — competitive landscape report
- Higher bioavailability BNX sublingual tablets updates RSS · CI watch RSS
- Orexo AB portfolio CI
Frequently asked questions about Higher bioavailability BNX sublingual tablets
What is Higher bioavailability BNX sublingual tablets?
How does Higher bioavailability BNX sublingual tablets work?
What is Higher bioavailability BNX sublingual tablets used for?
Who makes Higher bioavailability BNX sublingual tablets?
Is Higher bioavailability BNX sublingual tablets also known as anything else?
What drug class is Higher bioavailability BNX sublingual tablets in?
What development phase is Higher bioavailability BNX sublingual tablets in?
What are the side effects of Higher bioavailability BNX sublingual tablets?
What does Higher bioavailability BNX sublingual tablets target?
Related
- Drug class: All Opioid partial agonist drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Orexo AB — full pipeline
- Therapeutic area: All drugs in Pain management; Opioid use disorder
- Indication: Drugs for Opioid use disorder (maintenance treatment)
- Indication: Drugs for Moderate to severe pain
- Also known as: OX219, Zubsolv, Buprenorphine/naloxone sublingual tablets
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing